Mint Pharmaceuticals Listed by 8base Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

When a pharmaceutical company appears on a ransomware group's leak site, the practical stakes fall first on people whose personal or health-related information may have been among the files taken. Employees, contractors, suppliers, and anyone whose details sit in corporate systems can face identity misuse, targeted phishing, or longer-term privacy harm even when the exact scale remains unknown.

On 30 November 2024, Mint Pharmaceuticals, a Canadian generic-drug manufacturer based in Mississauga, Ontario, was listed by the 8base ransomware group. Public detail is limited: the number of people affected is unknown, and the only description available is that internal files were allegedly exfiltrated in a ransomware attack. That listing is a claim by the group, not an independently confirmed disclosure of what was taken or who was reached.

What happened

According to the available record, Mint Pharmaceuticals was listed by 8base on 30 November 2024. The report states that internal files were exfiltrated in a ransomware attack. No confirmed count of affected individuals has been published, no specific date of intrusion has been disclosed, and no technical method of initial access has been detailed in the public summary. The listing itself is presented by the threat actor; it has not been independently verified in the facts provided. Beyond the claim of file exfiltration, further operational details remain undisclosed.

Inside 8base

8base is a ransomware operation that has been publicly documented since 2022–2023 as practising double extortion: encrypting systems while also stealing data and threatening to publish it on a dedicated leak site if payment is not made. The group typically posts victim names, sometimes with sample files or countdown timers, and has targeted organisations across multiple sectors, including manufacturing, professional services, and healthcare-adjacent businesses. Its public communications emphasise pressure through data exposure rather than solely through operational disruption. In this case, the only claim tied specifically to Mint Pharmaceuticals is the leak-site listing itself; no additional statements by the group about this victim appear in the provided facts.

About Mint Pharmaceuticals

Mint Pharmaceuticals is a Canadian-owned generic pharmaceutical company headquartered in Mississauga, Ontario. Founded in 2007, it develops and supplies affordable generic medicines and healthcare solutions to the Canadian market, emphasising product differentiation, supply reliability, and service. Organisations of this type routinely hold employee records, supplier contracts, quality and regulatory documentation, distribution data, and sometimes limited patient or pharmacy-related information required for product tracking and compliance. A breach at a pharmaceutical manufacturer is consequential because the sector sits at the intersection of personal data, commercial intellectual property, and regulated supply chains; disruption or exposure can affect both individual privacy and the integrity of medicine distribution.

The information in question

The facts name the exposed material only as “internal files exfiltrated in a ransomware attack.” No further breakdown—such as whether the files contained employee identifiers, financial records, customer lists, manufacturing formulas, or regulatory submissions—has been disclosed. Pharmaceutical companies typically maintain human-resources data, vendor agreements, batch records, and correspondence with health authorities. Because the exact contents remain unconfirmed, it is not possible to state which of those categories, if any, were among the files claimed to have been taken. Readers should treat any specific data-type assertions beyond the official summary as unverified.

What's at stake

For individuals whose information may have been present, the concrete risks include phishing that leverages real names or internal context, credential stuffing if passwords or email addresses were stored, and potential identity-related fraud if government identifiers or banking details were included. For the organisation, stakes include regulatory scrutiny under Canadian privacy law, possible contractual notifications to partners, reputational damage, and the operational cost of recovery and investigation. Because the number of people affected is unknown and the precise data types are undisclosed, the full scope of exposure cannot yet be measured; the absence of confirmed numbers does not eliminate the need for caution among those connected to the company.

What to do if you're exposed

If you have worked for, contracted with, or otherwise shared personal information with Mint Pharmaceuticals, treat the listing as a reason to take basic protective steps while awaiting any official notification. Practical first actions include:

• Monitor bank and credit accounts for unexpected activity and consider a credit freeze or fraud alert if you believe sensitive identifiers may have been involved.
• Change passwords on any accounts that reused credentials associated with work email or company systems, and enable multi-factor authentication wherever available.
• Be alert to phishing emails or calls that reference the company, internal projects, or personal details that could have come from corporate files.
• Retain any official breach notice you receive and follow the contact channels it provides rather than unsolicited offers of “help.”
• Run a free exposure scan of your email address against known breach data sets to see whether your information has already appeared in other incidents.

Public detail on this incident remains limited. Until Mint Pharmaceuticals or regulators publish a fuller accounting, the safest posture is measured vigilance rather than assumption that no personal data was involved.

AICompiled with AI assistance from public sources and published under our editorial standards.